Pfizer Inc., of New York, said the Phase III INTORSECT study testing Torisel (temsirolimus) in patients with advanced renal cell carcinoma whose disease had progressed on or after Sutent (sunitinib malate) therapy did not meet the primary endpoint of prolonging progression-free survival (PFS) when compared to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG

S.L.A. Pharma AG, of Basel, Switzerland, reported top-line data from its Phase II study testing four doses of Nalcol, an oral formulation of naloxone (2.5 mg, 5 mg, 10 mg and 20 mg) in treating opioid-induced constipation in patients with persistent noncancer pain, showing statistical significant for increasing spontaneous bowel movements (SBM) against placebo and baseline

Clavis Pharma ASA, of Oslo, Norway, reported that partner Clovis Oncology Inc., of Boulder, Colo., received notification from the independent data monitoring committee that 64 percent of the 360 metastatic pancreatic cancer patients enrolled in the pivotal LEAP study testing CP-4126 (also known as CO-101) were classified as hENT1-low

Pharmanest AB, of Stockholm, Sweden, said the first patient was dosed in a 15-patient, open-label Phase I study testing SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion

Mesoblast Ltd., of Melbourne, Australia, said its Phase II study testing allogeneic Mesenchymal Precursor Cells (MPCs) for nonsurgical restoration of degenerated intervertebral discs and treatment of lower back pain has enrolled 50 percent of the total study patients

SanBio Inc., of Mountain View, Calif., said it completed enrollment in the first dose cohort in its Phase I/IIa study testing allogeneic stem cell therapy product SB623 in patients with chronic deficits resulting from previous stroke injuries

Cytori Therapeutics Inc., of San Diego, said the European Journal of Surgical Oncology published data from the 71-patient RESTORE-2 study testing autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for reconstruction of the breast after cancer surgery

Sangamo BioSciences Inc., of Richmond, Calif., said data from Phase I studies testing SB-728-T in HIV-infected subjects showed that viral load initially increased as expected during the treatment interruption (TI) of HAART therapy in all six subjects, followed by a 0.8 to > 2.0-log reduction in viral load from peak observed in three of six patients with the highest estimated circulating levels of cells with biallelic modification of their CCR5 genes

placebo in postoperative pain control following major joint replacement surgery and an open-label, active-comparator study testing ARX-01 against intravenous patient-controlled analgesia with morphine

Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported interim results from an ongoing Phase II study testing protease inhibitor Incivek (telaprevir) in combination with pegylated interferon and ribavirin in patients who are co-infected with genotype 1 hepatitis C virus (HCV) and HIV

Baxter International Inc., of Deerfield, Ill., said it started a pivotal Phase III study testing adult autologous CD34-positive stem cells to increase exercise capacity in patients with chronic myocardial ischemia

Cytokinetics Inc., of South San Francisco, said it started a Phase I study testing multiple oral formulations of omecamtiv mecarbil in healthy volunteers

Oragenics Inc., of Tampa, Fla., said a 32-patient study testing its weight-loss agent LPT3-04 over a 12-week period showed a statistically and clinically significant reduction in body weight in healthy, overweight and mildly obese adult volunteers

CSL Behring LLC, of King of Prussia, Pa., said results from a Phase I study testing recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia showed the drug was well tolerated and lasted longer in the body, due to its prolonged half-life, compared with existing Factor IX treatment options

AB Science SA, of Paris, reported data from a Phase II study testing masitinib against Sutent (sunitinib, Pfizer Inc.) in Gleevec (imatinib, Novartis AG)-resistant gastrointestinal stromal tumors (GIST

Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, reported top-line results from the first study testing the combined effects of LX4211 , a sodium glucose transporter 1 and 2 inhibitor, with DPP-4 inhibitor Januvia (sitagliptin, Merck & Co. Inc.), showing that the combination produced lower blood glucose levels after meals compared to sitagliptin alone (p = 0.012

Amicus Therapeutics Inc., of Cranbury, N.J., said preliminary results from an ongoing Phase II drug-drug interaction study testing two doses of migalastat HCl co-administered with enzyme replacement therapy (agalsidase beta or agalsidase alfa) in up to 24 males diagnosed with Fabry disease showed increases in levels of active enzyme in plasma and skin that demonstrate a positive drug-drug interaction between migalastat HCl and agalsidase beta

Taris Biomedical Inc., of Lexington, Mass., said it started a Phase II study testing LiRIS, a product designed to deliver lidocaine over an extended period directly to the bladder to relieve symptoms associated with interstitial cystitis

Ltd., of Osaka, Japan, reported additional analyses from the previously reported EMERALD Phase III studies testing peginesatide in dialysis patients with anemia due to chronic kidney disease (CKD), showing that once-monthly peginesatide maintained Hb levels in CKD patients on dialysis with anemia